About Frontier Biotechnologies Inc. Company

The company was founded in 2013 and is committed to the research, development, production and sale of innovative drugs for unmet major clinical needs. The company is a pioneer enterprise in the field of innovative antiviral drug research. In particular, it has international competitiveness in the long-term treatment of HIV and immunotherapy segments, and has formed an international business pattern based in China and facing the world. The company's main business is to adhere to the core values of “patient-centered, innovative solutions, and promote human health”, and research and develop safe, effective, novel drugs with significant clinical value and global competitiveness on a global scale in response to unmet clinical needs. The company's main products: Aikonin, FB1002, FB6001, FB3002, FB4001 and other products under development. Corporate honors: “24th China Patent Gold Award” and “First Jiangsu Patent Award Excellence Award”. The company won the honorary title of “Jiangsu Specialized and New Small and Medium Enterprises”, “China's Top 30 Innovative Small Molecule Pharmaceutical Enterprises of the Year”, “2022 Biotechnology Innovation Award”, “2022 Investment Pioneer Award”, “2022 China Biomedical Industry Value List Top 10 Most Growing Small Molecule Innovative Drug Companies”; in 2022, it won the honorary title of “2022 Investment Pioneer Award”, 2018 China's Top Ten Medical Science and Technology News, 2018 Innovative Drugs Innovative enterprises, 2016 Jiangsu Double Innovation Team, key overseas Chinese entrepreneurship teams, outstanding enterprises in the 6th China Innovation and Entrepreneurship Competition, etc.